MedPath

Efficacy of Infliximab comparing with Cyclophosphamide in refractory uveitis in Behcet’s diseases

Phase 3
Conditions
Refractory uveitis in patients with Behcet.
Behcet's disease
Registration Number
IRCT20180110038297N1
Lead Sponsor
Zanjan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Behcet’s disease
Refractory uveitis
Retinal vesiculitis

Exclusion Criteria

Patient dissatisfaction
Contraindications for administration of Infliximab or cyclophosphamide
Non response to medication

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath